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A B S T R A C T
Pharmaceutical agents (PAs) are commonly prescribed in companion animal practice in the United Kingdom.
However, little is known about PA prescription on a population-level, particularly with respect to PAs authorised
for human use alone prescribed via the veterinary cascade; this raises important questions regarding the eﬃcacy
and safety of PAs prescribed to companion animals. This study explored new approaches for describing PA
prescription, diversity and co-prescription in dogs, cats and rabbits utilising electronic health records (EHRs)
from a sentinel network of 457 companion animal-treating veterinary sites throughout the UK over a 2-year
period (2014–2016).
A novel text mining-based identiﬁcation and classiﬁcation methodology was utilised to semi-automatically
map practitioner-deﬁned product descriptions recorded in 918,333 EHRs from 413,870 dogs encompassing
1,242,270 prescriptions; 352,730 EHRs from 200,541 cats encompassing 491,554 prescriptions, and 22,526
EHRS from 13,398 rabbits encompassing 18,490 prescriptions respectively. PA prescription as a percentage of
booked consultations was 65.4% (95% conﬁdence interval, CI, 64.6–66.3) in dogs; in cats it was 69.1% (95% CI,
67.9–70.2) and in rabbits, 56.3% (95% CI, 54.7–57.8). Vaccines were the most commonly prescribed PAs in all
three species, with antibiotics, antimycotics, and parasiticides also commonly prescribed. PA prescription uti-
lising products authorised for human use only (hence, ‘human-authorised’) comprised 5.1% (95% CI, 4.7–5.5) of
total canine prescription events; in cats it was 2.8% (95% CI, 2.6–3.0), and in rabbits, 7.8% (95% CI, 6.5–9.0).
The most commonly prescribed human-authorised PA in dogs was metronidazole (antibiotic); in cats and rabbits
it was ranitidine (H2 histamine receptor antagonist). Using a new approach utilising the Simpson’s Diversity
Index (an ecological measure of relative animal, plant etc. species abundance), we identiﬁed diﬀerences in
prescription based on presenting complaint and species, with rabbits generally exposed to a less diverse range of
PAs than dogs or cats, potentially reﬂecting the paucity of authorised PAs for use in rabbits. Finally, through a
novel application of network analysis, we demonstrated the existence of three major co-prescription groups
(preventive health; treatment of disease, and euthanasia); a trend commonly observed in practice.
This study represents the ﬁrst time PA prescription has been described across all pharmaceutical families in a
large population of companion animals, encompassing PAs authorised for both veterinary and human-only use.
These data form a baseline against which future studies could be compared, and provides some useful tools for
understanding PA comparative eﬃcacy and risks when prescribed in the varied setting of clinical practice.
1. Introduction
Pharmaceutical agent (PA) prescription is an essential component of
companion animal veterinary practice. However, lack of available,
structured population-level data on PA prescription has resulted in a
limited capacity to assess the comparative eﬃcacy and risks of PAs
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being prescribed to clinically-aﬀected animals living outside of the
controlled conditions of a clinical eﬃcacy trial (pharmacosurveillance).
The increasing digitisation of animal health records, most notably in
developed countries, together with recent advances in health infor-
matics research, has provided an unprecedented opportunity to ﬁll this
gap (O’Neill et al., 2014; Sánchez-Vizcaíno et al., 2015).
In human medicine, the utility of electronic health records (EHRs)
for eﬀective pharmacosurveillance has been well demonstrated. Such
systems have the potential to provide rapid monitoring and commu-
nication of population experience (Eguale et al., 2010; Rowlingson
et al., 2013), identifying rare events as well as previously unseen
variability in response to PA prescription associated with sub-popula-
tion genetic diversity (Patel and Kaelber, 2014; Tamblyn et al., 2016).
Key areas of pharmacosurveillance research have focused on adverse
drug reactions and polypharmacy, the latter being deﬁned as con-
current prescription of multiple distinct PAs to a single person or animal
(Eguale et al., 2010; Cavallo et al., 2013; Sutherland et al., 2015; Urfer
et al., 2016).
Expanding prescription surveillance beyond adverse drug reaction
monitoring (pharmacovigilance, the ‘risks’) to also include PA eﬃcacy
assessment (pharmacosurveillance, the ‘beneﬁts and the risks’) would
represent a signiﬁcant development for companion animal veterinary
practice. In the United Kingdom, pharmacovigilance is led by the
Veterinary Medicine Directorate through a voluntary reporting service
(Veterinary Medicines Directorate, 2017). Whilst such services provide
population-level data on adverse drug reactions, they are generally
associated with an un-quantiﬁed level of under-reporting. When a PA is
not available to treat a particular condition in a species under their
care, the veterinary surgeon responsible for the animal may in parti-
cular circumstances (for example to avoid causing unacceptable suf-
fering) prescribe an unauthorised PA under the veterinary cascade;
these might include PAs authorised for use in other animal species, PAs
authorised for human use only (hence, ‘human-authorised’), or im-
ported medicines (Veterinary Medicines Directorate, 2013; Ramsey,
2017a,b). Currently there are no means by which human-authorised PA
prescription can be monitored at the population-level; this raises im-
portant questions regarding the eﬃcacy and safety of such PAs when
prescribed to companion animals.
More recently, as EHRs have become more available, they have
been used to address questions of timely importance, particularly re-
lating to antibiotic prescription in light of the global concern relating to
antimicrobial resistance (Mateus et al., 2011; Radford et al., 2011;
Buckland et al., 2016; Singleton et al., 2017). Although these studies
have shown important trends in antibiotic prescription, to date they
have not been able to look at concurrent use of other PAs within the
same consultation (co-prescription), despite evidence of antibiotics
being co-prescribed with other non-antibiotic PAs (German et al., 2010;
Jones et al., 2014). Developing an understanding of what veterinary
surgeons prescribe in addition to, or instead of, antibiotics will be ne-
cessary to enhance stewardship at the population-level.
Whilst these studies point to the potential of veterinary EHRs to
augment existing pharmacosurveillance, two features must be ad-
dressed before the full beneﬁts of these new data can be realised.
Firstly, the scale and complexity of EHR databases require new ways to
analyse health records, and generate population-level statistics.
Secondly, due to a lack of a centrally agreed PA classiﬁcation and ter-
minology system within the veterinary sector O’Neill et al., 2014), in-
dividual veterinary practices frequently develop their own personalised
nomenclatures when referring to for PA prescription within the EHR. In
this regard, categorising PAs to an agreed and common ontology may
be more complex in animal rather than human health, the latter fre-
quently beneﬁtting from the use of standardised PA lists (Tamblyn
et al., 2016).
In this study, we have addressed the issues of prescription data
scale, complexity and inconsistency using data collected over 2 years
from a large sentinel network of UK-based companion animal veter-
inary practices. We describe a text mining approach to map variable
practitioner-deﬁned PAs to taxonomies, and propose two new metrics
to summarise population-level PA prescription, namely prescription
diversity and social network analysis for co-prescription visualisation.
Using these combined approaches, we have been able to describe, in
various degrees of detail, intra- and inter-species variability in the
manner with which PAs are prescribed in companion animal practice.
2. Materials and methods
2.1. Data collection
Electronic Health Records (EHRs) were collected in near real-time
from booked consultations in volunteer UK veterinary practices taking
part in the Small Animal Veterinary Surveillance Network (SAVSNET)
between 1 April 2014 and 31 March 2016. A more complete description
of the data collection protocol has been previously described (Sánchez-
Vizcaíno et al., 2015). A veterinary practice (n=216) was deﬁned as a
single veterinary business, whereas a site (s) (n= 457) also included all
branches that form a veterinary practice. In addition to a range of an-
imal signalment data (e.g. age, sex, breed etc.), each EHR also included
a free text product description deﬁned by individual practices to record
everything supplied at the time of each consultation. At the end of each
consultation, practitioners participating in SAVSNET also code each
EHR by selecting one of ten main presenting complaints consisting of
gastroenteric, respiratory, pruritus, trauma, tumour, kidney disease,
other unwell, post-operative, vaccination and other healthy to indicate
the main reason why the animal presented for the given consultation
(Supplementary Material, Table 1).
2.2. Pharmaceutical agent prescription identiﬁcation
The product description ﬁeld of the EHR was utilised to identify
Pharmaceutical Agent (PA) prescription. Initially, a set of 52,267 pro-
duct descriptions (1 April 2014 - 26 August 2015) were manually de-
termined to contain PA prescription by reference to the Veterinary
Medicine Directorate’s Product Information Database for veterinary
authorised PAs, and the electronic Medicines Compendium (Datapharm
Communications) for PAs authorised for human use alone. PAs were
manually categorised, via partial reference to the ATCvet reference
schema (World Health Organisation, 2018), into a hierarchical struc-
ture whereby each PA could be summarised into both a pharmaceutical
family (PF) e.g. antibiotic, and pharmaceutical class (PC) e.g. ﬂuor-
oquinolone. A total of 26 PFs and 274 PCs were identiﬁed. The classi-
ﬁcation system used can be downloaded as a supplement to this article.
PAs were further categorised into those authorised for veterinary use
and those authorised for human use only. A third group was devised
(hence, ‘generic’) that consisted of active substances authorised for
prescription in both humans and animals, but was recorded within the
EHR using a term which did expressly state whether the product was
veterinary- or human-authorised e.g. ‘co-amox’. Whilst the majority of
product descriptions could be identiﬁed to speciﬁc active substance, the
‘vaccine’, ‘neurological’, ‘euthanasia’ and ‘replacement agent’ (veter-
inary- or human-authorised pharmaceutical products intended for re-
hydration, vitamin and/or mineral replacement) PFs frequently
Acronyms
EHR Electronic health record
PA Pharmaceutical agent
PC Pharmaceutical class
PD Prescription diversity
PF Pharmaceutical family
SAVSNET Small animal veterinary surveillance network
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contained descriptors where we were unable to determine the speciﬁc
PA prescribed e.g. ‘1x dog annual booster’. Hence, it was not possible to
summarise these PFs beyond family level.
Following this initial manual categorisation, a list of prescription-
identifying strings (n=1984) was formulated to identify prescription-
containing product descriptions in a new larger data set suitable for
further analysis (n unique product descriptions= 95,709; 1 April 2014
- 31 March 2016). Before these strings were applied to the dataset a
sequence of regular expressions were applied to product descriptions to
exclude those relating to diagnostic tests which could be misidentiﬁed
as containing a PA prescription e.g. phenobarbitone toxicity test (5318
unique product descriptions excluded); insulin syringes which could be
mistaken for a prescription of insulin (211 unique product descriptions
excluded), and product descriptions containing references to a refund
(22 unique product descriptions excluded) (Supplementary Material,
Table 2). PA prescription identifying strings were then applied, with a
total of 1759 strings being utilised to identify 56,699 unique product
descriptions pertaining to a PA prescription.
2.3. Pharmaceutical agent prescription diversity
We deﬁne PA Prescription Diversity (PD) as ‘the frequency and
variety with which a practice prescribes pharmaceutical classes (PC)
within a determined pharmaceutical family (PF)’. In this study, we
calculate PD using an adaptation of the Simpson’s Diversity Index, an
equation utilised most often in ecology to provide a quantitative mea-
sure of relative animal, plant etc. species abundance within a particular
geographical area over a deﬁned timeframe (Allaby, 2010), adjusted to
a 0–1 scale where 1 represents maximal diversity. We intend this
measure to distil otherwise complex prescription data into a single
metric that summarises the propensity of prescribers towards particular
PCs within a PF. The PD equation is as follows:
= −
∑ −
−
PD
np np
NP NP
1
( 1)
( 1)i
i i
i i
Where i=individual practice; np=number of prescriptions of a par-
ticular PC within a PF, and NP= total number of prescriptions within a
PF. For example, take practice ‘A’: a particular PF, ‘X’, contains 4 PCs
known as X1, X2, X3 and X4 respectively. Practice ‘A’ prescribed a PA
within the PF ‘X’ on 2000 occasions within the surveillance period,
these PA prescriptions were split by PC as follows: X1= 800, X2= 400,
X3= 400, X4= 400. The completed equation would therefore appear
as thus:
= −
× − + × −
+ × − + × −
× −
PD 1
((800 (800 1) (400 (400 1)
(400 (400 1) (400 (400 1))
2000 (2000 1)A
PDA=0.72
Fig. 1. Pharmaceutical co-prescription network model construction, sparsiﬁcation and formation to detect group structure. Size of each Pharmaceutical Family (PF)
node is relative to number of prescriptions, and edge width is relative to frequency of co-prescription between each PF. Diagrams refer to points along ﬁnal model
formation as follows: (A) Pharmaceutical class-level co-prescription network; (B) PF-level co-prescription network; (C) Prescription frequency sparsiﬁed; (D) Co-
prescription frequency sparsiﬁed; (E) Dogs: Final model with group structure (E), cats (F), and rabbits (G). AB= antibiotic; AF= anti-inﬂammatory;
AM=antimycotic; CVS= cardiovascular; ECT= ectoparasiticide; EDC=endocrine; END=endectocide; ENDO= endoparasiticide; EUTH= euthanasia;
GI= gastrointestinal; NEUR=neurological; REP= replacement agent; V= vaccine.
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Due to some PFs containing a greater range of available PCs, each PF
will possess a natural PD limit. For example, a ‘completely diverse’ PF
(where all available PCs have been prescribed evenly) containing four
PCs will possess a PD of 0.75, whereas a PF containing eight PCs will
possess a PD of 0.88. As such, PD should be interpreted only within a
PF, and should not be used for comparisons with other PFs. Here, we
benchmarked practices against each other, rather than against each PFs
theoretical maximum PD, to avoid establishing practically unreachable
‘targets’.
For brevity we demonstrated the application of the PD metric using
the ﬁve main PFs associated with treating infectious agents (antibiotic,
antimycotic, ectoparasiticide, endectocide and endoparasiticide); these
are all commonly prescribed in all three species and have critical re-
levance in the context of antimicrobial resistance to both animals and
humans (Cuny et al., 2015; Zhang, 2016).
2.4. Co-prescription network
Co-prescription was here deﬁned as prescription of two or more PAs
belonging to a diﬀerent PF within the same booked consultation. Three
co-prescription networks were created for each species, using social
network analytical methods, via the igraph package available in R
(Csardi, 2006). A node referred to a particular PF, with the size of the
node being relative to frequency of prescription. An edge referred to a
co-prescription event between diﬀerent PFs, with edge weight being
relative to frequency of co-prescription. As a number of PFs were rarely
prescribed and some co-prescription links were uncommon, the net-
works were then sparsiﬁed, retaining PF nodes that contributed 0.5% or
more to total prescriptions, and edges that contributed in excess of the
mean co-prescription frequency for each of the three networks. The
network was then examined for group structure via a propagating label
algorithm, with the aim of deﬁning PF groups of preferential co-pre-
scription. In short, this algorithm utilised the structure of the network
itself by enabling a uniquely labelled node to adopt the label that the
majority of its neighbours possess in an iterative process until groups of
densely connected nodes (if present) formed a consensus on a single
label, indicating presence of a group (Raghavan et al., 2007). A visual
summary of this methodological process can be observed in Fig. 1.
2.5. Statistical analysis
Consultation and prescription-level proportions and conﬁdence in-
tervals were calculated to adjust for clustering (bootstrap method,
n=5000 samples) within sites and at animal level within practices
(Lesnoﬀ and Lancelot, 2012). Repeat prescriptions for the same animal
were considered separately in consultation-level analyses. A pairwise
Wilcoxon rank sum test with Bonferroni correction to account for
multiple comparisons (hence, ‘Wilcoxon’) was performed to examine PF
variability (calculated at practice-level) between animal species for
selected PFs. Kendall correlations (t test to reject null hypothesis) were
performed for testing the association between PD and the total number
of consults contributed by each practice, and PD and the number of PA
prescription events by each practice for dogs, cats, and rabbits for se-
lected PFs. Statistical signiﬁcance was deﬁned as P < 0.05 and all
analyses were carried out using R version 3.4.1 (R Core Team, 2017).
3. Results
Data were available from 413,870 dogs (from 918,333 Electronic
Health Records, EHRs), 200,541 cats (352,730 EHRs) and 13,398 rab-
bits (22,526 EHRs). This yielded a total number of 1,241,888 recorded
Pharmaceutical Agent (PA) prescription events in dogs; 490,872 in cats,
and 18,530 in rabbits. The percentage of booked consultations where at
least one prescription was recorded was 65% (95% conﬁdence interval
(CI) 65-66) in dogs; whereas in cats it was 69% (95% CI 68-70), and in
rabbits it was 56% (95% CI 55-58). Dogs recorded at least one pre-
scription event for all 26 Pharmaceutical Families (PFs) whereas cats
recorded prescription for 24 PFs and rabbits, 17 PFs. Vaccines were the
most commonly prescribed PF in all species, though rabbits (22%, 95%
CI 20-23) were less commonly prescribed vaccines than dogs (28%,
95% CI 27-29) or cats (30%, 95% CI 29-31). Conversely, rabbits were
euthanised the most frequently (4%, 95% CI 4-5) compared to dogs
Table 1
Rate per 10,000 consultations for dogs, cats and rabbits where a particular pharmaceutical family was prescribed. A blank space signiﬁes no prescription of the PF in
that species.
Pharmaceutical family Dog Cat Rabbit
Rate per 10,000 consults 95% Conf. interv. Rate per 10,000 consults 95% Conf. interv. Rate per 10,000 consults 95% Conf. interv.
Allergy 36 31–42 5 4–6
Anabolic 2 2–3 34 25–43 1 0-3
Anti-infective 0.01 0.00–0.03
Anti-inﬂammatory 1916 1848–1982 1783 1711–1857 1246 1170–1322
Antibiotic 1879 1820–1938 1749 1685–1814 1653 1551–1754
Antimycotic 394 380–408 74 69–79 52 41–63
Antiviral 0.01 0.00–0.03 2 1-2
Bladder 0.03 0.00–0.08 0.3 0.0-0.5
Cardiovascular 101 94–108 137 124–151 11 6–16
Chemotherapeutic 3 2–4 3 2-4
Diagnostic 0.2 0.1–0.4 0.1 0.0–0.2 0.4 0.0–1.3
Ectoparasiticide 965 882–1048 1342 1248–1435 124 103–145
Endectocide 1161 1069–1252 1673 1570-1775 334 300–369
Endocrine 43 38–48 142 129–155
Endoparasiticide 944 872–1016 1415 1332–1500 246 209–282
Euthanasia 103 97–110 229 217–240 431 395–467
Gastrointestinal 263 247–278 196 178–214 624 565–683
Hormone 37 33–40 14 8–20 2 0–4
Immunosuppression 34 31–38 6 5–7
Liver 3 3–4 4 3–4
Neurological 378 348–407 214 190–238 263 209–317
Ocular 19 14–25 5 4-6 12 5–18
Renal 50 20–70
Replacement agent 49 42–56 129 111–146 74 52–96
Respiratory 13 11–16 28 23–32 12 7–18
Vaccine 2792 2700–2885 3023 2913–3132 2159 2020–2298
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(1%, 95% CI 1-1) or cats (2%, 95% CI 2-2) (Table 1). At the individual
animal level, 81% of dogs (95% CI 80–82) and 81% of cats (95% CI 80-
82) had been prescribed at least one PA within the 2-year study period;
levels were lower in rabbits (68%; 95% CI 67-70).
3.1. Authorisation
Overall prescription of PAs authorised for human use only (human-
authorised) were relatively low in each species. In dogs, 5% (95% CI 5-
5) were human-authorised, 93% (95% CI 93-94) of prescriptions were
authorised for veterinary use, and 2% (95% CI 2-2) generic. In cats 3%
(95% CI 3-3) were human-authorised, 96% (95% CI 96-96) veterinary-
authorised, and 1% (95% CI 1-2) generic. In rabbits 8% (95% CI 7-9)
were human-authorised, 90% (95% CI 88-91) veterinary-authorised,
and 2% (95% CI 2-3) generic.
A summary of the percentage of PA prescriptions which utilised
products authorised for human-only use by PF can be seen in Table 2.
The three most commonly prescribed human-authorised PAs in dogs
were metronidazole (antibiotic), tramadol (neurological), and raniti-
dine (gastrointestinal), representing 16%, 12% and 12% of total
human-authorised prescriptions in dogs, respectively. This compared
with ranitidine (gastrointestinal), dexamethasone (anti-inﬂammatory)
and neomycin sulphate (antibiotic) in cats, representing 13%, 8% and
7% of total human-authorised prescriptions in cats, respectively. The
three most commonly prescribed human-authorised PAs in rabbits were
ranitidine (gastrointestinal), trimethoprim potentiated sulfamethox-
azole (antibiotic) and cisapride (gastrointestinal), representing 38%,
10% and 9% of total human-authorised prescriptions in rabbits, re-
spectively.
3.2. Pharmaceutical class and prescription diversity
For the ﬁve PFs analysed (antibiotic, antimycotic, ectoparasiticide,
endectocide and endoparasiticide) we found key diﬀerences between
species at the level of PC, particularly for antibiotic prescription. For
dogs, the most commonly prescribed antibiotic was clavulanic acid
potentiated amoxicillin (29% of antibiotic prescriptions); for anti-
mycotics, imidazoles (60%); for ectoparasiticides, neonicotinoids
(76%); for endectocides, milbemycin (97%), and for endoparasiticides,
quinolines (78%) (Supplementary Material, Table 3).
For cats, the most commonly prescribed antibiotic was 3rd genera-
tion cephalosporins (36% of antibiotic prescriptions); for antimycotics,
polyenes (58%); for ectoparasiticides, neonicotinoids (65%); for en-
dectocides, milbemycin (87%), and for endoparasiticides, quinolines
(81%) (Supplementary Material, Table 4).
For rabbits, ﬂuoroquinolones represented the most commonly pre-
scribed antibiotic (49% of antibiotic prescriptions); for antimycotics,
polyenes (52%); for ectoparasiticides, insect growth regulators (59%);
Table 2
Summary of pharmaceutical agent prescriptions for dogs, cats, and rabbits summarised by pharmaceutical family, and the percentage of total prescription events for
each PF that included products authorised for human use only (Human).
Pharmaceutical
family
Dog Cat Rabbit
Number (%) of prescription events Human
(%)
Number (%)
of prescription events
Human
(%)
Number (%)
of prescription events
Human (%)
Vaccine 324727 (26.1) –a 110245 (22.5) – 4907 (26.5) –
Antibiotic 218700 (17.6) 11.4 71088 (14.5) 5.7 4481 (24.2) 10.9
Anti-inﬂammatory 209644 (16.9) 3.2 77244 (15.7) 1.6 3132 (16.9) 3.6
Endectocide 113887 (9.2) 0.0 63401 (12.9) 0.0 765 (4.1) 0.0
Endoparasiticide 108802 (8.8) 0.0 59997 (12.2) 0.0 556 (3.0) 0.0
Ectoparasiticide 98768 (8.0) 0.0 55895 (11.4) 0.0 285 (1.5) 0.0
Neurological 49241 (4.0) – 11,899 (2.4) – 1037 (5.6) –
Antimycotic 36766 (3.0) 0.3 2611 (0.5) 0.1 118 (0.6) 0.8
Gastrointestinal 30981 (2.5) 33.9 8962 (1.8) 51.3 1914 (10.3) 35.8
Cardiovascular 14554 (1.2) 5.2 6720 (1.4) 26.8 29 (0.2) 34.5
Euthanasia 10057 (0.8) – 8458 (1.7) – 1051 (5.7) –
Replacement agent 7320 (0.6) – 5316 (1.1) – 188 (1.0) –
Endocrine 4235 (0.3) 14.8 5443 (1.1) 0.7 0
Hormone 3452 (0.3) 0.3 496 (0.1) 0.0 5 (0.03) 0.0
Allergy 3381 (0.3) 100.0 186 (0.04) 100.0 0
Immunosuppression 3285 (0.3) 7.1 207 (0.04) 1.0 0
Ocular 1861 (0.1) 99.9 186 (0.04) 100.0 27 (0.2) 100.0
Respiratory 1305 (0.1) 2.5 1010 (0.2) 6.8 31 (0.2) 0.0
Chemotherapeutic 319 (0.03) 87.1 116 (0.02) 94.0 0
Liver 304 (0.02) 100.0 125 (0.03) 100.0 0
Anabolic 219 (0.02) 0.0 1201 (0.2) 0.0 3 (0.02) 0.0
Renal 49 (0.004) 100.0 0 0
Diagnostic 26 (0.002) 100.0 4 (0.001) 100.0 1 (0.01) 100.0
Bladder 3 (0.0002) 100.0 9 (0.002) 100.0 0
Anti-infective 1 (0.0001) 100.0 0 0
Antiviral 1 (0.0001) 0.0 53 (0.01) 66.0 0
a Not able to accurately estimate.
Table 3
Summary of pharmaceutical classes prescribed and median prescription di-
versity (PD) for ﬁve exemplar pharmaceutical families in dogs, cats and rabbits.
Pharmaceutical
family
Animal
species
Total classes
prescribed
Median classes
prescribed
Median PD
Antibiotic Dog 21 13 0.83
Cat 20 10 0.75
Rabbit 17 4 0.64
Antimycotic Dog 8 2 0.44
Cat 4 2 0.44
Rabbit 4 1 0.00
Ectoparasiticide Dog 9 5 0.14
Cat 7 3 0.23
Rabbit 5 2 0.33
Endectocide Dog 2 2 0.00
Cat 2 2 0.02
Rabbit 2 1 0.00
Endoparasiticide Dog 4 3 0.12
Cat 4 3 0.14
Rabbit 4 1 0.00
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for endectocides, avermectins (98%), and for endoparasticides, benzi-
midazoles (98%) (Supplementary Material, Table 5).
PD was calculated for each of the ﬁve exemplar PFs across all
contributing veterinary practices (Table 3). Dogs (median PD 0.83)
showed signiﬁcantly greater antibiotic PD compared to cats (median PD
0.75) and rabbits (median PD 0.64). Similarly, cats reported greater PD
compared to rabbits (Wilcoxon P < 0.001 for all comparisons). In
dogs, practices reporting higher PD values tended to contribute more
canine consultations (Kendall correlation, τ=0.18, P < 0.001) and
more antibiotic prescriptions (Kendall correlation, τ=0.17, P <
0.001) to the project, though these relationships were weak.
Considering antimycotic prescription, no signiﬁcant variation was
observed between dogs (median PD 0.44) and cats (median PD 0.44;
Wilcoxon P= 1.00); dogs and rabbits (median PD 0.00; Wilcoxon P=
0.35), or cats and rabbits (Wilcoxon P= 0.77). In dogs, practices re-
porting higher PD values tended to also contribute more consultations
(Kendall correlation, τ=0.13, P= 0.01) and antimycotic prescriptions
(Kendall correlation, τ=0.10, P= 0.03) to the project, though these
relationships were weak.
For ectoparasiticide prescription, no signiﬁcant variation was ob-
served between dogs (median PD 0.14) and cats (median PD 0.23;
Wilcoxon P= 0.50); dogs and rabbits (median PD 0.33; Wilcoxon P=
1.00), or cats and rabbits (P= 1.00). In both dogs (Kendall correlation,
τ=0.25, P < 0.001) and cats (Kendall correlation, τ=0.13, P=
0.01), practices reporting higher ectoparasiticide PD values also tended
to contribute more consultations to the project, though these relation-
ships were weak.
For endectocide prescription, dogs (median PD 0.00) were sig-
niﬁcantly less diverse than cats (median PD 0.02) and rabbits (median
PD 0.00); cats were signiﬁcantly more diverse than rabbits (Wilcoxon
P < 0.001 for all comparisons). In both dogs (Kendall correlation,
τ=0.18, P < 0.001) and cats (Kendall correlation, τ=0.17, P <
0.001), practices reporting higher PD values also tended to contribute
more consultations, though these relationships were weak.
Regarding endoparasiticide prescription, dogs (median PD 0.12)
showed signiﬁcantly greater diversity compared to rabbits (median PD
0.00; Wilcoxon P < 0.001). Cats (median PD 0.14) also showed sig-
niﬁcantly greater diversity compared to rabbits (Wilcoxon P < 0.001),
though no signiﬁcant diﬀerence was observed between dogs and cats
(Wilcoxon P= 1.00). In both dogs and cats, practices reporting higher
PD values also tended to contribute a greater number of consultations
(Kendall correlation, dogs; τ=0.16, P < 0.001 and cats; τ=0.25,
P < 0.001) and prescriptions (Kendall correlation, dogs; τ=0.10,
P= 0.03 and cats; τ=0.22, P < 0.001) to the project, though these
relationships were weak.
For dogs and cats, the antibiotic PF was selected for further de-
monstration of how PD might be developed into a benchmark; both on a
practice and population-level. At the practice-level no signiﬁcant cor-
relation was observed between antibiotic PD and the frequency with
which antibiotics were prescribed as a percentage of total booked
consultations (hence, ‘prescription frequency’) in dogs (Kendall corre-
lation, τ=0.07, P= 0.12) or cats (Kendall correlation, τ=−0.07,
P= 0.11), though a clear single cluster was observed in both species
(Fig. 2). Fig. 3 displays a suggested practice summary whereby each
contributory practice can be been ranked into quintiles based sepa-
rately on their values for antibiotic PD and prescription frequency.
Antibiotic prescriptions were ﬁnally classiﬁed by route of adminis-
tration and by main presenting complaint. Signiﬁcant practice-level PD
variation was observed between dogs (median PD 0.66) and cats
(median PD 0.62) for antibiotics authorised for systemic administration
(Wilcoxon P < 0.001). Similarly, signiﬁcant variation was observed
between dogs (median PD 0.66) and cats (median PD 0.60) for anti-
biotics authorised for topical administration (Wilcoxon P < 0.001),
suggesting that dogs were prescribed a more diverse range of antibiotics
than cats across both administration categories. For systemically-au-
thorised antibiotics, PD was further compared against prescription
frequency. Some main presenting complaints showed notable variation
in PD between species despite similar prescription frequencies e.g.
pruritus and post-operative care (Table 4).
3.3. Pharmaceutical agent co-prescription
In dogs, co-prescription occurred in 40% (n=243,038) of total
prescribing consultations; this compared with 45% for cats
(n=108,546) and 23% (n=2884) of total prescribing consultations
for rabbits. Antibiotics and anti-inﬂammatories were the most com-
monly co-prescribed PFs in dogs and rabbits; however in cats the most
commonly co-prescribed PFs were endoparasiticides and endectocides
Fig. 2. Antibiotic prescription: Practice-level comparison of dog and cat antibiotic prescription diversity (PD) and the proportion of consultations where an antibiotic
was prescribed as a proportion of total consultations contributed by each practice (n=216). Blue lines refer to the means and associated 95% conﬁdence intervals of
each metric. Point size is relational to number of consultations contributed by each practice where increased point size indicates a greater relative contribution. The
contour plot indicates point density, with red indicating maximal point density (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article).
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(Supplementary Material, Table 6).
Sparsiﬁed co-prescription networks for dogs, cats and rabbits ﬁtted
to detect group structure can be seen in Fig. 1E–G. Co-prescription
formed into three equivalent groups for all three species. The ﬁrst group
(Fig. 3, Group 1) included vaccines and parasiticides; the second group
(Fig. 1, Group 2) contained a number of PFs generally focused on
treating ‘unhealthy’ animals, with antibiotics and anti-inﬂammatories
being central to this group. The third group (Fig. 1, Group 3) consisted
entirely of PAs only associated with euthanasia. Not surprisingly, eu-
thanasia appeared completely separate from any other node in all three
networks, suggesting lack of network membership. Cat co-prescriptions
formed a fourth isolated group consisting entirely of the endocrine PF
(Fig. 1, Group 4).
4. Discussion
Electronic health records (EHRs) collected at scale can complement
existing pharmacovigilance data, and provide new insight into the ef-
ﬁcacy, and risks, of PA prescription and co-prescription in genetically
and phenotypically heterogeneous populations. Here we describe a new
methodology that enables variable EHR prescription data to be mapped
to standardised terms, providing a ﬁrst broad overview of both
veterinary- and human-authorised prescription in a large population of
companion animal-treating veterinary practices. We further proposed a
new diversity metric for quantifying prescription variability at popu-
lation- and practice-levels. Finally, co-prescription was common and,
through novel application of network analyses, divided into three
preferential co-prescription groups corresponding to ‘healthy’, ‘un-
healthy’ or ‘euthanasia’ consultations.
Currently, estimates of companion animal veterinary-authorised PA
prescription are limited to information provided by Market
Authorisation Holders at a wholesale level (Hunt et al., 2015a,b) and
sporadic research papers in response to issues of current importance,
such as antimicrobial resistance (Buckland et al., 2016; Singleton et al.,
2017). By making PA prescriptions accessible from EHRs, we can now
expand monitoring to all PFs across a range of species. We show that PA
prescription was common in this population, particularly in dogs and
cats in comparison to rabbits. Vaccines were the PF prescribed most
frequently in all species, reaﬃrming the importance of preventive
health consultations in veterinary practice (Robinson et al., 2015), and
the continued perceived importance of sometimes life threatening
vaccine-preventable infections in cats (Day et al., 2016; Afonso et al.,
2017), dogs (Clegg et al., 2011; Day et al., 2016) and rabbits (Westcott
and Choudhury, 2015).
Population data on PA prescriptions utilising products authorised
for human use alone are extremely limited, despite such products
forming an important treatment option for companion animals
(Buckland et al., 2016; Singleton et al., 2017; Hunt et al., 2015b).
Prescription of human-authorised products has the potential to increase
the risk of adverse drug reactions in animals, and such cases have been
described (Short et al., 2014; Diesel, 2015; Giuﬀrida, 2016). However,
the Market Authorisation Holder has no obligation to investigate ad-
verse drug reaction reports when a human-authorised product is pre-
scribed to an animal (Diesel, 2015), meaning that safety knowledge
regarding such products is limited. Here we have been able to identify
the most commonly prescribed human-authorised PAs in this popula-
tion. We found that ranitidine, a H2 histamine receptor antagonist, was
a commonly prescribed human-authorised PA in all three species, de-
spite another H2 histamine receptor antagonist (cimetidine) being au-
thorised for use in dogs. This might be due to a prokinetic eﬀect pro-
duced by ranitidine in contrast to cimetidine, or the availability of
ranitidine in an oral liquid form, although other factors may be
Fig. 3. Antibiotic prescription: Dog and cat antibiotic prescription frequency (as a percentage of total consultations) and antibiotic Prescription Diversity (PD)
practice-level benchmarking matrix. Prescription frequency and PD were ranked separately by practice (n=216) and sorted into evenly spaced quintiles (1= lowest
prescription frequency and PD) before being summarised by the number of practices that placed into each of the pairwise quintile groups.
Table 4
Systemically-authorised antibiotic prescription frequency (percentage of con-
sultations where a systemically-authorised antibiotic was prescribed) and
median prescription diversity (PD) in dogs and cats, grouped by main pre-
senting complaint.
Main presenting
complaint
Dog Cat
Prescription
frequency (%)
Median PD Prescription
frequency (%)
Median PD
Gastroenteric 38.2 0.57 28.9 0.67
Respiratory 40.4 0.56 49.9 0.64
Pruritus 25.5 0.58 24.9 0.38
Trauma 21.3 0.46 50.1 0.56
Tumour 17.5 0.60 19.8 0.60
Kidney disease 26.8 0.45 18.9 0.50
Other unwell 20.3 0.62 24.9 0.61
Post-operative 9.9 0.56 9.6 0.67
Other healthy 1.4 0.66 8.4 0.62
Vaccination 7.0 0.74 1.4 0.67
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involved (Ramsey, 2017a,b). Although metronidazole was frequently
prescribed, the authorisation of a veterinary-authorised metronidazole
formulation in December 2015 means that human-authorised me-
tronidazole prescription is likely to decrease (Veterinary Medicines
Directorate, 2018). Hunt et al. (2015a,b) previously identiﬁed tramadol
as a frequently prescribed human-authorised PA in dogs, its popularity
possibly due to it being an alternative to non-steroidal anti-in-
ﬂammatory drugs. We found that rabbits were prescribed human-au-
thorised PAs more frequently than dogs or cats. This might reﬂect a
greater propensity towards prescribing PFs more commonly associated
with human-authorised PA prescription e.g. the gastrointestinal PF,
and/or a relative paucity of rabbit-authorised PAs - there is little eco-
nomic beneﬁt to investing in a marketing authorisation for a relatively
‘minor species’.
It is of tantamount importance, especially regarding antibiotic
stewardship, to develop summary prescription statistics that are ac-
cessible to practising veterinary surgeons, researchers and policy ma-
kers alike. In ecology, species diversity calculations are used to sum-
marise species variety and frequency ‘captured’ within a particular
area/time (Allaby, 2010). Using similar approaches (modiﬁed Peterson
Index), interventional studies within human hospitals showed an as-
sociation between increased antibiotic prescription diversity and con-
current decreased resistant bacteria prevalence (Sandiumenge et al.,
2006; Takesue et al., 2010). We initially attempted this approach,
though the more varied nature of the SAVSNET population produced
ﬁndings that were heavily inﬂuenced by the number of prescriptions
recorded by each veterinary practice (data not presented). It was hence
concluded that a modiﬁcation of the Simpson’s Diversity Index (Allaby,
2010) would provide a more appropriate measure in this population.
In the SAVSNET population we found that rabbits were generally
associated with less diverse prescription compared to dogs or cats,
possibly again reﬂecting a paucity of authorised PAs in rabbits. Across
all species, in many cases a single PC was pre-dominantly prescribed
within a PF, potentially reﬂecting practice policy and/or PA ‘on-shelf’
availability. We further found variation between clinical presentations
not immediately apparent by examining prescription frequency alone.
This was particularly apparent for pruritus, where cats displayed re-
duced systemically-authorised antibiotic prescription diversity com-
pared to dogs, despite similar prescription frequency. This is consistent
with the relative prescription dominance of particular antibiotic classes
in cats as previously reported (Buckland et al., 2016; Burke et al., 2017;
Singleton et al., 2017). A weak, inconsistent level of correlation was
noted between prescription diversity and the number of consultations
and prescriptions provided by each veterinary practice. This might re-
ﬂect greater case or care diversity in larger veterinary practices. Of
course many factors may impact on prescription diversity in a popu-
lation such as that sampled by SAVSNET, including market dominance,
standard operating procedures, perceived or actual leaders in eﬃcacy,
habit and preferred suppliers, especially since the emergence of veter-
inary sector corporatisation. We propose the methods presented here as
a simple means to describe prescription variability between sub-popu-
lations at local practice and national levels.
The issue of polypharmacy is of increasing importance to human
medicine, particularly in association with an ageing population (Urfer
et al., 2016); the same is likely to be true of veterinary medicine
(Hunter and Isaza, 2017). Whilst prescription of multiple PAs might be
wholly appropriate to combat complex clinical situations, drug-drug
interactions have been identiﬁed as a major cause of adverse drug re-
actions (Cavallo et al., 2013; Sutherland et al., 2015). As veterinary
prescribing broadens in scope and complexity (Riviere, 2007), there is
concern that understanding of veterinary drug-drug interactions is
limited (Aidasani et al., 2008), resulting in under-recognition and
under-reporting of adverse drug reactions (Hunt et al., 2015a,b;
Belshaw et al., 2016). Instigating routine co-prescription surveillance in
veterinary practice would provide clear targets for drug-drug interac-
tion studies that would enable anticipation of, rather than reaction to,
adverse drug reaction reports (Aidasani et al., 2008). EHR surveillance
could further complement existing voluntary veterinary reporting, po-
tentially also providing real-time feedback of immediate beneﬁt to the
patient (Page et al., 2017).
Pharmaceutical co-prescription was shown to be common in all
species in this population, though less common for rabbits. Whilst social
network analysis has traditionally been associated with social science
research, its potential for health research is being increasingly realised
(Valente, 2010). There have been some attempts to visualise co-pre-
scription networks in public health studies (Cavallo et al., 2013;
Sutherland et al., 2015), though to the authors knowledge, none yet
exist in veterinary medicine. The methods presented here identiﬁed
three similar co-prescription groups summarised as ‘healthy’ consulta-
tions primarily concerned with preventive health, ‘unhealthy’ con-
sultations primarily concerned with treating disease, and ‘euthanasia’
consultations. This pattern would be familiar with most veterinary
surgeons (Robinson et al., 2015), and provides conﬁdence that this
method might be of use for identifying previously unobserved co-pre-
scription trends when applied to particular sub-populations of animals
and/or clinical presentations. Cats also demonstrated a fourth group
concerned with treatment of endocrine disorders; highlighting in-
creased disorder prevalence in this species e.g. hyperthyroidism (Higgs
et al., 2014). Some of the PFs that appeared to be preferentially co-
prescribed, notably parasiticides, are likely the result of multivalent
products.
There are some limitations with utilising EHRs for the purpose de-
scribed in this study. Reporting of PA prescriptions depends on veter-
inary practitioners recording PAs within their practice management
software; as such unrecorded products or products described in a
fashion that was impossible for the method described here to identify
would be missed. Prescription events were considered on a consulta-
tion-by-consultation basis; hence, prescription frequency might be re-
latively over-stated for PAs where repeated prescriptions/applications
could be expected, such as vaccinations or PAs associated with man-
agement of chronic conditions. Whilst the aim of this study was to
broadly monitor and classify PAs into a single hierarchy based on the
most likely intended use of such PAs, it is clear that many PAs can be
administered for multiple purposes e.g. corticosteroids as anti-in-
ﬂammatories or immunosuppressives (Cohn, 2010); it was beyond the
scope of this study to explore motivation for prescription in individual
cases, though this could be achieved via linkage of prescription data
presented here to free text information in the clinical narrative
(Radford et al., 2011; Burke et al., 2017). Practices contributing data to
SAVSNET are recruited on convenience so cannot necessarily be con-
sidered to be representative of the wider UK population. The main
presenting complaint function does enable all consultations to be en-
coded; however variable interpretations of the main presenting com-
plaint is possible.
5. Conclusions
We have developed pharmacosurveillance tools to enable identiﬁ-
cation, description and benchmarking of all pharmaceutical agent
prescriptions, including those authorised for human use only, utilising
EHR data collected from a large-scale population of companion animal-
treating veterinary practices. Here we have demonstrated pharmaceu-
tical agents authorised for human use only that are commonly pre-
scribed to companion animals; these should be prioritised for further
eﬃcacy and risk investigation. We have established prescription di-
versity as a useful research tool to identify previously hidden popula-
tion-level prescription behaviour, and suggest this metric as a useful
addition to practice-level benchmarking capability. Finally, though co-
prescription data can be of considerable complexity, we have suggested
a simple means by which these data can be simpliﬁed to uncover
ﬁndings of value to the veterinary profession.
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